• Avalo Therapeutics priced an underwritten public offering of 19,730,000 common shares, with pre-funded warrants in lieu of common stock for 1,400,000 shares.
• Common shares priced at USD 17.75; pre-funded warrants priced at USD 17.749 with a USD 0.001 per-share exercise price.
• Gross proceeds expected at about USD 375 million before fees, assuming no exercise of a 30-day option for underwriters to buy up to 3,169,500 additional shares.
• Closing expected May 7, 2026, subject to customary conditions.
• Net proceeds earmarked to advance clinical development of abdakibart through Phase 3 topline data release, with remainder for working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605052333PRIMZONEFULLFEED9714068) on May 06, 2026, and is solely responsible for the information contained therein.